PCM
RARE icon

Peregrine Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Peregrine Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-189,520
Closed -$6.89M – 348
2025
Q2 		$6.89M Buy
189,520
+20,053
+12% +$723K 0.21% 138
2025
Q1 		$6.14M Buy
169,467
+5,579
+3% +$232K 0.2% 148
2024
Q4 		$6.89M Buy
163,888
+29,684
+22% +$1.47M 0.2% 140
2024
Q3 		$7.46M Sell
134,204
-14,609
-10% -$744K 0.23% 117
2024
Q2 		$6.12M Buy
148,813
+29,474
+25% +$1.26M 0.18% 199
2024
Q1 		$5.57M Buy
119,339
+39
+0% +$1.84K 0.16% 220
2023
Q4 		$5.7M Sell
119,300
-20,570
-15% -$797K 0.17% 215
2023
Q3 		$4.99M Sell
139,870
-8,774
-6% -$348K 0.15% 232
2023
Q2 		$6.86M Sell
148,644
-43
-0% -$2K 0.19% 223
2023
Q1 		$5.96M Buy
148,687
+4,381
+3% +$188K 0.17% 232
2022
Q4 		$6.69M Buy
144,306
+25,377
+21% +$998K 0.21% 218
2022
Q3 		$4.92M Sell
118,929
-6,577
-5% -$338K 0.16% 232
2022
Q2 		$7.49M Sell
125,506
-98
-0.1% -$6.03K 0.23% 198
2022
Q1 		$9.12M Buy
+125,604
New +$8.74M 0.22% 193

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Peregrine Capital Management's RARE Position: Q3 2025 in Review

Peregrine Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 189,520 shares — an estimated $6.89M sold.

Peregrine Capital Management first reported a position in RARE in Q1 2022 and held it in 14 quarters. The position peaked at $9.12M in Q1 2022. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Peregrine Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 189,520 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $6.89M.
  • Peregrine Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and held it in 14 quarters.
  • Peregrine Capital Management's Ultragenyx Pharmaceutical position peaked at $9.12M in Q1 2022.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Peregrine Capital Management's 13F filing for Q3 2025, filed 23 Oct 2025.